

MAIA Biotechnology

Apr 01, 2026

MAIA Reports Two-Year Survival Data At Medical Conference

Healthcare

MAIA

NYSE

Rating

Outperform

Unchanged

Current Price

\$1.40

Target Price

\$14.00

Market Capitalization

84.94m

Shares Outstanding

60.67m

Float

41.06m

Institutional Holdings

4.15%

12-Month Low/High

\$0.87/\$3.19

Average 90-Day Volume

1170000

Fiscal Year End

12/31/2026

New Data Presented Shows Long-Term Survival. MAIA presented data from its Phase 2 THIO-101 trial at the European Lung Cancer Congress 2026 (ELCC) held recently in Copenhagen, Denmark. The presentation included data from patients with non-small cell lung cancer (NSCLC) who had relapsed after treatment with standard chemotherapy. Data from 8 patients showed survival exceeding 2 years and greatly exceeded the expected survival for patients at their stage of disease.


Phase 2 Trial Design. THIO-101 was designed in three stages. Part A was basic safety, and Part B was a dose-finding stage. These two stages treated a total of 79 patients. The ongoing Part C is an expansion stage enrolling up to 48 participants in Asia and Europe. The patients are treated with ateganosine (aka THIO) followed by cemiplimab (Libtayo, from Regeneron).

This Is The First Long Term Survival Data Following Trial Completion. The data were from 8 patients treated in Parts A and B of the Phase 2 THIO-101 trial. These patients all had relapsed or become refractory to 1 or 2 courses of standard chemotherapy, including treatment with a checkpoint inhibitor (CPI) alone. The patients completed therapy over the 24 months of the trial, with 1 patient completing 2 cycles of therapy with a survival follow-up of 725 days off therapy. The patients did not receive additional therapy after completing the trial regimen.


Patients Survived Beyond Two Years. Four patients receiving second-line therapy survived for over 30 months, compared with a published survival of 10.5 months for chemotherapy or checkpoint inhibitor monotherapy. One patient receiving the regimen as third-line (3L) therapy survived 33 months, compared with the expected survival for the advanced disease population of 5.8 months. Out of the 8 patients, 5 remain alive with continued follow-up.

Conclusion. Patients in the trial had advanced disease with relapsed NSCLC. We see these data as additional evidence of a sustainable response from combination treatment with ateganosine and cemiplimab. These data are consistent with prior findings showing improvements in overall survival, progression-free survival, and median survival in patients with ICI-resistant and chemo-resistant NSCLC. We are reiterating our Outperform rating and \$14 price target.

Equity Research

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology
(212) 896-4625, rleboyer@noblecapitalmarkets.com,  Connect on LinkedIn

Noble Capital Markets, Inc.

Trading: (561) 998-5489 Sales: (561) 998-5491
noblecapitalmarkets.com | Follow Noble on LinkedIn 

Refer to the last two pages for Analyst Certification & Disclosures

Revenues (\$ MIL)

Period	2022A	2023E	2024E
Q1	0.0	0.0A	0.0E
Q2	0.0	0.0A	0.0E
Q3	0.0	0.0E	0.0E
Q4	0.0	0.0E	0.0E
	0.0	0.0E	0.0E


EPS (\$)

Period	2022A	2023E	2024E
Q1	(0.50)	(0.38)A	(0.45)E
Q2	(0.40)	(0.35)A	(0.50)E
Q3	(0.48)	(0.39)E	(0.47)E
Q4	(0.37)	(0.43)E	(0.50)E
	(1.75)	(1.55)E	(1.92)E

Summary. MAIA presented new survival data from its Phase 2 THIO-101 trial in patients with non-small cell lung cancer (NSCLC). The presentation was made at the European Lung Cancer Congress 2026 (ELCC) held recently in Copenhagen, Denmark, with detailed treatment data from 8 patients who exceeded two years of survival, greatly surpassing the expected survival for patients with their stages of disease.

Phase 2 Trial Design. THIO-101 was designed in three stages. Part A was basic safety, while Part B was a dose-finding stage testing three doses. These two stages treated a total of 79 patients. The ongoing Part C is an expansion stage enrolling up to 48 participants in Asia and Europe. The patients are treated with ateganosine (aka THIO) followed by cemiplimab (Libtayo, from Regeneron).

Exhibit 1. Design of the Phase 2 THIO-101 Trial. Using a modified 3+3 design, Part A was a safety lead-in that enrolled 10 patients receiving a 360mg dose of ateganosine (IV 120 mg, on days 1 to 3), followed by 350 mg cemiplimab on day 5 every three weeks. Part B was a dose-finding portion that used a Simon 2-stage design. This stage enrolled 79 patients to test three dose levels (360, 180, or 60 mg) followed by cemiplimab every third week for up to 1 year. In Part C, up to 48 patients (one arm with the combination of ateganosine and cemiplimab, one arm with ateganosine as monotherapy). Up to 100 patients are planned for Part D.



Primary endpoints: Safety, ORR, DCR (CR, PR and SD).

Secondary endpoints: DoR; PFS; OS.


Exploratory endpoints: PK and PD (activity of Ateganosine in circulating tumor cells measured by specific biomarkers).

Source: MAIA Biotechnology, Inc.

Long-Term Survival Data Following Trial Completion. The data was from 8 patients treated in Parts A and B of the Phase 2 THIO-101 trial. These patients all had relapsed or become refractory to 1 or 2 courses of treatment with standard chemotherapy, including treatment with a checkpoint inhibitor (CPI) alone. The patients completed 29-34 cycles of therapy over the 24 months of the trial, with 1 patient completing 2 cycles of therapy with a survival follow-up of 725 days off therapy. None of the patients received additional therapy after completing the trial regimen.

Four patients receiving second-line (2L) therapy survived over 30 months, compared with published survival for chemotherapy or checkpoint inhibitor monotherapy of 10.5 months. One patient receiving the regimen as third-line (3L) therapy survived 33 months. Expected survival in this advanced disease population is 5.8 months. Out of the 8 patients, 5 remain alive with continued follow-up.


Exhibit 2. Efficacy Findings After Patient Treatment. Partial responses by RECIST 1.1 criteria were reported for 3 patients (2 receiving second-line and 1 receiving third-line). Two of these patients initially received a 360 mg dose of Ateganosine and then changed to a 180 mg dose on days 78 and 92. One of these patients received the 180 mg dose of Ateganosine from the initiation of treatment to the end of treatment.



- Spider plot shows the target lesion change from baseline over time for these 8 patients (Figure 5).
- Ateganosine with cemiplimab shows sustained response between the baseline and the last dose of treatment, as well as from the last dose of treatment to the duration of survival follow-up.

Source: MAIA Biotechnology, Inc.

Exhibit 3. Tumor Shrinkage Compared To Baseline. The spider plot shows the target lesion change from baseline over time for these 8 patients. Ateganosine with cemiplimab shows sustained response between the baseline and the last dose of treatment, as well as from the last dose of treatment to the duration of survival follow-up.



Source: MAIA Biotechnology, Inc.

Conclusion. We see these data as additional evidence of a sustainable response from combination treatment with ateganosine and cemiplimab. These data are consistent with previous data that show clinically meaningful improvements in overall survival, progression-free survival, and median survival in patients with ICI-resistant and chemo-resistant NSCLC. We are reiterating our Outperform rating and \$14 price target.

Company Profile

MAIA Biotechnology is a clinical-stage biotechnology company developing telomere-targeting drugs to treat cancer. The lead product, THIO, is a modified nucleoside in a Phase 2 trial for non-small cell lung cancer in combination with Libtayo (cimiplimab, from Regeneron). A Phase 3 trial began treating patients in December 2025.

Fundamental Analysis

In our analysis, we give MAIA Biotechnology a rating of 4.0 checks out of 5 checks. This falls in the upper half of our "above average" range. Our positive fundamental rating is based on the company's position in the oncology and immuno-oncology fields which are expected to continue their growth in sales and market share. Management has extensive experience in research and development, with a track record of developing successful products in the pharmaceutical industry. For further explanation of our fundamental analysis, please refer to the disclosures at the end of this report.

Valuation Summary

Our Outperform rating and valuation are based on our FY2027 EPS estimate of \$2.70, discounted at 30% per year with a multiple of 15X for a price target of \$14 per share. This correlates with a market valuation of about \$170 million, which we believe is justified for a novel immunotherapy drug serving several large patient populations and several orphan drug indications.



GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words "we", "us", or "our" are solely the responsibility of Noble Capital Markets, Inc. ("Noble") and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.

IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. ("Noble"). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst's judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.

The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the "Company") covered by the Noble Research Division and referred to in this research report.

The Company in this report is a participant in the Company Sponsored Research Program ("CSR"); Noble receives compensation from the Company for such participation. No part of the CSR compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report.

Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) within the next 3 months.

Noble is not a market maker in the Company.

FUNDAMENTAL ASSESSMENT

The fundamental assessment rating system is designed to provide insights on the company's fundamentals both on a macro level, which incorporates a company's market opportunity and competitive position, and on a micro/company specific level. The micro/company specific attributes include operating & financial leverage, and corporate governance/management. The number of check marks that a company receives is designed to provide a quick reference and easy determination of the company's fundamentals based upon the following five attributes of the company (weighting reflects the importance of each attribute in the overall scoring of company's fundamental analysis):

Attribute	Weighting
Corporate Governance/Management	20%
Market Opportunity Analysis	20%
Competitive Position	20%
Operating Leverage	20%
Financial Leverage	20%

For each attribute, the analysts score the company from a low of zero to a high of ten based upon the analysis described below. The final rating and resulting check marks is a result of dividing the overall score (out of 100%) by ten.

Rating	Score	Checks
Superior	9.1 to 10	Five Checks
Superior	8.1 to 9	Four & A Half Checks
Above Average	7.1 to 8	Four Checks
Above Average	6.1 to 7	Three & A Half Checks
Average	5.1 to 6	Three Checks
Average	4 to 5	Two & A Half Checks
Below Average	3 to 3.9	Two Checks
Below Average	2 to 2.9	One & A Half Checks
Low Quality	0 to 1.9	One Check

While these are the attributes currently used for the analyst's fundamental analysis, the attributes and weighting may be reviewed, updated with additional attributes, and/or changed in the future based on discussions with the analysts and recommendations from the Director of Research.

Following is the description of each attribute in the fundamental analysis.

Corporate Governance/Management

We believe that a review of corporate governance and assessment of the senior management are important tools to determine investment merit. Good corporate governance aligns management with the interests of stakeholders. As such, analysts are to rank the company on the basis of good corporate governance principles that may include rules and procedures, board composition and staggered term limits, rights and responsibilities, corporate objectives, monitoring of actions and policies, and accountability. In addition, analysts will assess issues with controlling shareholders and whether decisions have been made in the past that were in the interests of all shareholders. In addition, management will be assessed based on industry experience, expertise, and/or track record.

High ranking example: Board and management that is aligned with the interests of shareholders with incentives based on stock price appreciation and with an experienced management team known for exceptional shareholder returns.

Low ranking example: Concentrated ownership without independent directors that do not necessarily align with all shareholders' interests.

The Market Opportunity Analysis

In this review, the analyst assesses the company's macro environment as a measure of understanding the industry. Factors considered include the size and growth potential of the industry under various economic conditions, the emerging demands in the market, technological benefits/disruptions, competition, geographical opportunities, and customer demands/needs, and an assessment of supply and distribution channels. In addition, the analyst will review legal and regulatory trends, as well as potential shifts in consumer or social behavior and natural environment changes.

High rank example: A company in an industry that is growing revenues well above GDP rates (which are on average 2% plus) and/or may have unmet or underserved needs in a rapidly growing market opportunity.

Low rank example: A mature industry that is in secular decline and likely to grow below GDP rates.

Competitive Position

The evaluation of the company's competitive position is another macro environment attribute designed to measure the relevance, market share, position and value proposition, and sustainable differentiations of the company and its products/services within its industry. Ease of entry into the industry and the ability of other well-funded players to potentially enter the market would be determined. As such, the assessment would consider the company's strengths and advantages of its products/services against weaknesses and limitations. This may include the company's current brand awareness, pricing and cost structure, current market strategies and geographic penetration that may affect demand for its products/services. In addition, the company's competitors would be evaluated.

High rank example: An analyst would consider the company's product to be superior to its competitors and that should allow the company to gain market share.

Low rank example: A company with a "me-too" product that does not have any significant technology advantages in an industry that has low barriers to entry.

Operating Leverage

Simplistically, operating leverage is determined by the operating income relative to changes in revenue. The analyst will calculate the impact on sensitivity on gross margins and variable costs to determine operating leverage. The analyst will take into account the ability of the company to cut fixed and variable costs in a challenged revenue environment and technological changes that may impact operating expenses. In addition, the analyst is to assess corporate strategies that include capital investment, which may be required for sustainable revenue growth, marketing expenses, and the company's ability to attract and retain talent and/or employees. The analyst should focus on the revenue opportunity and determine the price elasticity of demand for the company's products or services. In other words, the analyst is to rank the company based on improved operating margins going forward on an absolute and relative basis.

High rank example: A company that has improving margins for the foreseeable future, with significant price elasticity.

Low rank example: A company that is in a challenged revenue environment with a fixed cost structure and limited ability to cut costs, indicating an outlook for declining margins.

Financial Leverage

A strict definition of financial leverage is total debt divided by total shareholder's equity. Financial leverage analysis is to determine the company's ability to improve shareholder value by means of utilizing its balance sheet to grow organically or to acquire assets. Analysts may look at the company's debt to cash flow leverage ratio, interest coverage ratios, or debt to equity ratios. In addition, the interest rate environment and the outlook for interest rates are a factor in determining the company's ability to manage financial leverage. Finally, the analyst is expected to determine the ability to service the debt given the industry and/or company profile, such as cyclical, barriers to entry, history of bankruptcy, consistency in revenue and profit growth, or predictability in sales and profits and large cash reserves. The analyst is expected to take into account capital intensity of the company and the anticipated of capital allocation decisions.

High rank example: A company with predictable and growing revenue and cash flow with modest debt levels. This may indicate that the company could improve shareholder value through growth investments, including acquisitions, using debt financing.

Low rank example: A company in a cyclical industry in a late stage economic cycle that has above average debt leverage and is in an industry that has a history of financial challenges, including bankruptcies.

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Senior Equity Research Analyst focusing on the Biotechnology and Specialty Pharmaceuticals industry. 16 years of industry experience. BA in Economics from Tulane University and an MBA from Columbia Business School. FINRA licenses 7, 24, 63, 86, 87

CONTINUING COVERAGE

Unless otherwise noted through the dropping of coverage or change in analyst, the analyst who wrote this research report will provide continuing coverage on this company through the publishing of research available through Noble Capital Market's distribution lists, website, third party distribution partners, and through Noble's affiliated website, channelchek.com.

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to by an investment advisor, that advisor may receive a benefit in respect of transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by . This report may not be reproduced, distributed or published for any purpose unless authorized by .

RESEARCH ANALYST CERTIFICATION**Independence Of View**

All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation

No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.

Ownership and Material Conflicts of Interest

Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

NOBLE RATINGS DEFINITIONS	% OF SECURITIES COVERED	% IB CLIENTS
Outperform: potential return is >15% above the current price	89%	15%
Market Perform: potential return is -15% to 15% of the current price	11%	2%
Underperform: potential return is >15% below the current price	0%	0%

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from "Buy" to "Outperform", from "Hold" to "Market Perform" and from "Sell" to "Underperform." The percentage relationships, as compared to current price (definitions), have remained the same.

Additional information is available upon request. The recipient of this report who wishes further information regarding the subject company or the disclosure information mentioned herein, should contact by mail or phone.

Noble Capital Markets, Inc.
150 E Palmetto Park Rd, Suite 110
Boca Raton, FL 33432
561-994-1191

Noble Life Science Partners is a division of Noble Capital Markets, Inc..

Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.

Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.

Member - SIPC (Securities Investor Protection Corporation)

Report ID: 28165